Second-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumor and Serum Biomarkers için istatistikler
Toplam ziyaret
views | |
---|---|
Second-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumor and Serum Biomarkers | 0 |
Aylık toplam ziyaret
views | |
---|---|
Ocak 2025 | 0 |
Şubat 2025 | 0 |
Mart 2025 | 0 |
Nisan 2025 | 0 |
Mayıs 2025 | 0 |
Haziran 2025 | 0 |
Temmuz 2025 | 0 |